Abstract: Described herein are microcapsules including a hydrophobic material-based core, preferably a perfume or a flavour, a shell and a mineral layer onto the shell. Also described herein is a process for the preparation of the microcapsules. Also described herein are perfuming compositions and consumer products including the microcapsules, in particular perfumed consumer products in the form of fine fragrance, home care or personal care products.

Abstract: Cosmetic blending devices for producing a cosmetic liquid from a solid-shell cosmetic ingredient capsule. The cosmetic blending devices include a lid, a base, a blending element configured to blend the capsule, and a drive mechanism configured to actuate the blending element. The cosmetic blending device may include a thermal element configured to change a temperature of the capsule. The thermal element may melt the capsule. The solid-shell cosmetic ingredient capsule comprises a shell defining an enclosed inner volume, and cosmetic material included in the enclosed inner volume. Methods of using the cosmetic blending devices comprise placing the solid-shell cosmetic ingredient capsule into the cosmetic blending device and blending the capsule to produce the cosmetic liquid. Methods of forming the solid-shell cosmetic ingredient capsule comprise forming a portion of the shell, adding the cosmetic material to the portion of the shell, and forming the remaining portion of the shell.

Abstract: The present invention relates to a composition for treating keratin fibres, notably human keratin fibres such as the hair, comprising at least one nonionic surfactant, 1,3-propanediol, at least one fatty substance other than fatty acids in a content greater than or equal to 10% by weight relative to the total weight of the composition, and at least one dye. The present invention also relates to a process for dyeing keratin fibres, such as the hair, wherein the composition as described previously is applied to said fibres. The present invention also relates to a process for dyeing keratin fibres such as the hair, wherein the composition as described previously, and comprising at least one dye, preferably chosen from oxidation dyes, direct dyes and mixtures thereof, is applied to said fibres. The present invention also relates to the use of the composition according to the invention for dyeing keratin fibres such as the hair.

Abstract: The present invention relates to a mixture comprising one or more dicaffeoylquinic acids and tocopherol. Further, the invention relates to a cosmetic composition, a composition for food or pleasure or a pharmaceutical composition comprising such a mixture. Moreover, the invention relates to the uses of dicaffeoylquinic acids, of mixtures comprising these or of compositions comprising such mixtures. Even further, the invention relates to the use of tocopherol for increasing the stability of one or more dicaffeoylquinic acids in a mixture or a composition.

Abstract: Compositions that have glycerol fatty acid esters and particular fatty acid amidoalkyl betaines and/or particular alkyl betaines can be used for the thickening of cosmetic formulations. The composition can also be used for thickening an aqueous formulation. The composition also has 3.0% by weight to 20% by weight of glycerol fatty acid esters, wherein the weight percentages are based on the overall composition.

Abstract: A personal cleansing composition includes a surfactant system that includes from 1.75% to 2.75% of a fatty acyl isethionate surfactant by weight of the composition; from 1.75% to 3.0% of a fatty acyl sarcosinate surfactant by weight of the composition; and from 7.75% to 9.75% of a zwitterionic surfactant by weight of composition. The zwitterionic surfactant includes a betaine. The cleansing composition has a pH from 5.5 to 7 the composition is substantially free of from alkyl sulfate and alkyl ether sulfate type of surfactants.

Abstract: A method of treating and preventing disease includes administering an amount of alkaline phosphatase to a subject effective to prevent biofilm, plaque formation, calculus, and incipient dental caries in the subject's oral cavity; to prevent plaque formation in the blood vessels and brain; to prevent colonization of bacteria in skin, in the gut, and other parts of the body. The administered composition is a dentifrice, is ingestible, is injectable, or is topically applied. The method can cure any disease that is due to bacterial plaque formation that's surface attachment initiated by LTA, LPS and/or Tau protein.

Abstract: Cosmetic treatment method comprising the application of a composition comprising at least one antioxidant and a Bifidobacterium species lysate The present invention relates to a method for the cosmetic treatment of the scalp and the hair, comprising the application of a composition comprising at least one particular antioxidant, a Bifidobacterium species lysate and water. Preferably, the cosmetic treatment method of the invention is a method for caring for and/or for conditioning said scalp and hair.

Abstract: An object is to provide a novel sebum secretion inhibition. Provided is a sebum secretion suppressor which is an agent containing a polysaccharide, in which at least a part of constituent sugars constituting the polysaccharide is one or more {for example, arabinogalactan, lipopolysaccharide (LPS), arabinoxylan and/or glucomannan} selected from the group consisting of arabinose, galactose, and xylose.

Abstract: A cosmetic composition containing a component (A): a film-forming polymer containing an M unit represented by (R1)3SiO1/2 and a Q unit represented by SiO4/2 (in the formula, R1 represents a hydrocarbon group having 1 or more and 12 or less carbon atoms and optionally substituted with fluorine, or a hydroxy group, and plural R1's can be the same as or different from each other), a component (B): a film-forming polymer other than the component (A), and a component (C): a volatile solvent, wherein the component (C) has a content of 50% by mass or more.

Abstract: Compositions and methods include magnesium sulfate or forskolin to treat erectile dysfunction, premature ejaculation, decreased libido, and benign prostatic hyperplasia in the male and orgasmic sexual dysfunction/decreased libido in the female. The compositions may be delivered topically or transdermally on the penis to reduce the symptoms of erectile dysfunction, premature ejaculation, low libido, by increasing blood flow to the penis, delivered topically in the ano-rectal or prostate region to reduce the symptoms of BPH by smooth muscle relaxation of the prostate, or by topical or transdermal application to the female genitalia, nipple and/or ano-rectal region, to treat low libido/orgasmic sexual dysfunction.

Abstract: Provided herein are stable, bioerodible films containing active ingredients, such as antimicrobial composition, antiviral compositions, antiretroviral compositions, and/or contraceptive compositions for intravaginal placement to provide prophylaxis against viral infections and contraception.

Abstract: A post-fabrication method for drug loading a medical device with an active pharmaceutical ingredient (API). Such medical devices can include a polymer matrix, where the polymer matrix, after exposure to a loading solution with the API, can exhibit a degree of swelling of the polymer matrix and/or a degree of swelling in which the polymer matrix increases in a dimension along an axis. Medical devices including a polymer matrix and an API are provided, where the API is loaded into the polymer matrix by adsorption and/or swelling after fabrication of the polymer matrix, wherein the medical device provides a substantially sustained release of the API for an extended period of time. The medical devices include intravaginal rings (IVR). Methods of treating a subject using the disclosed medical devices are also provided, including treating a subject with an IVR with one or more APIs loaded therein.

Abstract: The present disclosure provides for nasal compositions for antihypertensive drugs and methods for preparing the compositions. The compositions of the disclosure are particularly suitable for pediatric and geriatric populations, and patients with dysphagia, for treatment of conditions and diseases associated with hypertension, essential hypertension, hypertensive crisis, hypertensive emergency, hypertensive urgency, and other cardiovascular disease by administration, via nasal mucosa.

Abstract: An ocular delivery system useful for the treatment of glaucoma in subject in need thereof. Especially, a mucoadhesive solid or semisolid ocular delivery system that includes a matrix of preactivated thiomer of hyaluronic acid and one or more anti-glaucoma drugs. The ocular delivery system may be an ocular insert or an ocular film.

Abstract: The present disclosure is directed to floating gastroretentive dosage forms with prolonged gastric residence time. The disclosure also provides rapidly expanding sustained release or combined immediate release and sustained release formulations comprising drugs that require targeted release in the proximal gastrointestinal tract for maximum therapeutic benefit. The rapidly expanding floating gastroretentive dosage forms comprise a permeable elastic membrane providing desired characteristics for drug release and mechanical strength to maintain tablet integrity.

Abstract: A composition comprising an aqueous gel with therapeutically effective amounts of glycerin, polyacrylic acid, and a synthetic peptide. The synthetic peptide may comprise palmitoyl tripeptide-1 or palmitoyl tripeptide-7, and the addition of a therapeutically effective amount of pullulan or of extracts of microalgae or of macadamias may also be used.

Abstract: The disclosure relates to methods and compositions comprising atropine and a polymer in a gel formulation for decreasing saliva production and treating sialorrhea.

Abstract: The present invention provides a stable pharmaceutical composition comprising apomorphine and one or more pharmaceutically acceptable carriers in an injectable device. The present invention also provides a process for preparing the stable pharmaceutical composition.

Abstract: The present invention relates to oil in water nanoemulsions which are essentially free of propylene glycol. The nanovesicle formulations are particularly stable in regard to shelf life at different storage temperatures.

Abstract: Thickened microemulsions are described where hydrophobic liquid droplets are distributed in a continuous hydrophilic liquid phase. In relation to conventional oil-in-water (OIW) microemulsions, the described thickened microemulsions may be thought of as modified oil-in-water (MOIW) microemulsions, where both the “oil” and “water” phases of the microemulsion are modified. The oil phase droplets of the thickened MOIW microemulsion are modified with alcohol and an alcohol-lipid phase thickener and can solubilize alcohol-soluble species, including nonderivatized hormones. Preferably, the modified oil phase droplets of the thickened MOIW microemulsion directly solubilize nonderivatized hormones. The polar continuous “water” phase of the thickened MOIW microemulsion is modified with a continuous phase thickener. The modified oil phase droplets disperse into the modified polar continuous phase of the thickened MOIW microemulsion.

Abstract: The present disclosure provides all-natural nano- or micro-emulsions for the treatment of the skin, hair follicles, and related conditions, methods of using such nano- or micro-emulsions, and methods for preparing such nano- or micro-emulsions. The present disclosure relates to nano- or micro-emulsion formulations with improved bioavailability, time of onset, cellular permeability, and viscosity that can be suitable for topical, sublingual, oral, and/or nasal administrations. The current disclosure also includes compositions and methods for improving the bioavailability and the onset of actions arising from the particular components within the nano- or micro-emulsion formulations of the present disclosure.

Abstract: The present disclosure relates to nanoparticles and nanoparticulate compositions; methods of preparing such nanoparticles and nanoparticulate compositions; and associated methods of medical treatment and uses of such nanoparticles and nanoparticulate compositions for medical treatment, including the use of such nanoparticles for the manufacture of medicaments for medical treatment.

Abstract: A novel cationic lipid having a structure as represented by general formula (1), which specifically relates to a nitrogen-containing cationic lipid, and also relates to a liposome containing the cationic lipid, a liposome pharmaceutical composition containing said cationic lipid, preparation and application thereof. A cationic liposome containing the cationic lipid represented by formula (1), can improve the loading rate and transport rate of drugs, particularly nucleic acid drugs. The terminus of the novel cationic lipid can contain a fluorescent group or a targeting group, so that the cationic liposome pharmaceutical composition containing the cationic lipid can have fluorescent or targeting function.

Abstract: The present disclosure describes compositions, preparations, nanoparticles (such as lipid nanoparticles), and/or nanomaterials and methods of their use.

Abstract: A solid powder composition comprising: (i) one or more particles containing a nitrite salt and a proton source; or (ii) an agglomeration of particles, wherein the agglomeration of particles includes one or more particles containing a nitrite salt and one or more particles containing a proton source. Also disclosed are pharmaceutical compositions comprising the solid powder composition, methods of producing the solid powder composition, methods of treatment using the solid powder composition, materials and devices comprising the solid powder compositions method of making thereof and methods of implanting thereof into a human or animal body.

Abstract: Provided are a lyophilized vortioxetine pamoate powder for injection and a preparation method therefor. The prepared powder for injection product has good permeability and stability, and is very suitable for industrialization.

Abstract: The invention relates to a tablet comprising a salt of N-(8-(2-hydroxy benzoyl)amino)caprylic acid. The invention further relates to processes for the preparation such a tablet, and its use in medicine.

Abstract: A method for preparing a plant-based hard capsule for rapid disintegration, the method comprises: weighing a coagulant aid, dissolving in distilled water at 75-90° C., and stirring to obtain a first solution; maintaining a temperature of the first solution at 75-90° C., adding a gel-forming agent, and stirring; adding a film-forming agent with a weight percentage of 5%-25%, stirring, finally adding a plasticizer by a weight percentage of 0-3%, and stirring until the film-forming agent and the plasticizer are completely dissolved to obtain a material solution; leaving the material solution to stand at 45-60° C. to obtain a gel solution; and cooling the gel solution to 40-50° C., dipping the gel solution for forming, and drying for 100-200 minutes under a condition of 20-35° C. and a 40%-60% relative humidity; and demoulding, cutting, and combining together by sleeving to obtain the plant-based hard capsule for the rapid disintegration.

Abstract: An amorphous solid dispersions comprising an active pharmaceutical ingredient and pharmaceutical compositions comprising the amorphous solid dispersions. Also described herein are methods for preparing and using such compositions. In some embodiments, an amorphous solid dispersion comprises an active pharmaceutical ingredient such as palbociclib or neratinib, one or more acids, and a high-molecular weight material.

Abstract: The application discloses a formulation and method for increasing bioavailability of an orally administered drug.

Abstract: In one aspect, the disclosure relates to nanoclusters comprising cores comprising self-assembled unimolecular nanoparticles and biomimetic membrane coatings surrounding the cores, methods of making the same, and methods of treating and preventing restenosis using same. In some embodiments, the nanoclusters can contain an anti-restenotic drug. In one embodiment, the polymers and/or copolymers of the unimolecular nanoparticles can contain a hydrophobic group such as, for example, a phenylboronic ester. In a further embodiment, the biomimetic membrane can localize the nanoclusters at sites of vascular damage, at which time reactive oxygen species (ROS) at the sites of vascular damage cleave the hydrophobic groups from the polymers and/or copolymers, increasing hydrophilicity of the polymers and/or copolymers and allowing for greater tissue penetration of the de-clustered nanoclusters and nanoparticles.

Abstract: Provided are empty lipid nanoparticle compositions, and processes for their preparation, which are useful in the preparation of therapeutic or prophylactic lipid nanoparticle compositions comprising a therapeutic or prophylactic agent including, for example, nucleic acids such as mRNA.

Abstract: Provided herein are methods of using methanol, or a prodrug thereof, in therapy, e.g., for promoting an immune response, treating cancer, enhancing an immunotherapy and/or treating immune dysfunction. Also provided herein are methanol prodrugs of the following structural formula: Formula (I), or a pharmaceutically acceptable salt thereof, wherein values for the variables (e.g., R, X, R2, n) are as described herein.

Abstract: The present invention relates to compositions comprising 2?,4?-dihydroxy-3?,6?-dimethoxychalcone or a pharmaceutically acceptable salt thereof for use as a medicament. In particular, the present invention relates to compositions comprising 2?,4?-dihydroxy-3?,6?-dimethoxychalcone or a pharmaceutically acceptable salt thereof for use in the prevention and/or treatment of a disease associated with IL-23/IL-17 axis activation, except cancers.

Abstract: The nano liquid composition containing curcumin have the ability to treating burns and increasing the effect of scar healing obtained by homogenously mixing a curcumin nano ingredient with a foundation mixture in a ratio of 1:1 by emulsifying equipment. The composition overcomes the disadvantages of curcumin, an organic compound with a broad spectrum of activities, including hard to dissolve in water, poor stability, and rapidly transformed. In addition, the composition of the present invention is used at a dose of 0.05-0.1 mL/cm 2 of skin, with a frequency of twice daily, had increased effect of scar healing in experimental doxorubicin-induced mouse models of skin ulceration, increased concentration of hydroxyprolin in skin, improved skin microstructure compared to control models after 21 days of application; and had no systemic toxicity after 21 days of application in the doxorubicin-induced skin ulcered mouse.

Abstract: The present invention relates to the field of brain tumour treatment. The invention provides methods of killing brain tumour cells in these tissues using high concentrations of cytotoxic agents which are capable of binding strongly to normal brain extracellular matrix (ECM), but less strongly to extracellular matrix components in the tumour environment. The cytotoxic agent is a polyamine, e.g. spermidine or putrescine.

Abstract: The present invention is directed to pharmaceutical products, and to methods for the treatment of depression (e.g., major depressive disorder) and other diseases or disorders for which esketamine has a therapeutic benefit. In some embodiments, the methods are useful for the treatment of treatment-refractory or treatment-resistant depression or suicidal ideation. Methods of intranasal administration and devices for intranasal administration are also disclosed.

Abstract: Disclosed are a phenylephrine hydrochloride-containing tablet, a preparation method and use. The method for preparing a phenylephrine hydrochloride-containing tablet includes: mixing a granule A with other granules to be uniform to obtain a mixture, and subjecting the mixture to tablet pressing to obtain the phenylephrine hydrochloride-containing tablet; wherein the granule A is prepared by dry granulation, and contains phenylephrine hydrochloride as a single active pharmaceutically ingredient, the other granules comprise at least one selected from the group consisting of a granule B and a granule C, and the granule B contains acetaminophen as an active pharmaceutical ingredient, and the granule C contains dextromethorphan hydrobromide and chlorpheniramine maleate as active pharmaceutical ingredients.

Abstract: Provided are gastric residence systems comprising at least one drug-eluting component comprising methadone or a salt thereof, 35-50 wt % polycaprolactone, and 0.5-3 wt % poloxamer, and a rate-modulating release film coating the at least one co-extruded drug eluting component. The gastric residence systems comprising at least one drug-eluting component are configured to be maintained within a stomach of a human body for at least 48 hours and to release methadone for at least 48 hours, such that the at least one drug eluting component with the rate-modulating release film is configured to release at least 10% of the methadone or the salt thereof after the first 24 hours of residence within the stomach.

Abstract: Compositions comprising a substituted phenethylamine and methods of using the compositions for treating an inflammatory or neurological disorder in a subject in need thereof are disclosed. The substituted phenethylamine can be used at sub-hallucinogenic concentrations.

Abstract: The present disclosure provides pharmaceutical compositions for treating fungal, viral, and/or bacterial infections. The pharmaceutical compositions of the disclosure can comprise a cationic surfactant, a chelating agent, a pH modifier, and a solvent. The pharmaceutical compositions of the disclosure can be used to treat drug-sensitive or multidrug-resistant bacterial, viral, and/or fungal infections. In some embodiments, the chelating agent can be biodegradable.

Abstract: Compositions for managing post-prandial metabolic changes, including glycemic and lipid responses, and related methods of manufacture and use. A composition for attenuating post-prandial glycemic response (GR) and lipid response (LR) reduces risk of chronic metabolic diseases. Certain ingredients of the composition include resistant dextrin, corosolic acid, and chromium(III) picolinate, which may be combined together using a wet agglomeration or a dry mixing step. The agglomerated or dryly mixed ingredients may then be intimately dry blended with a flavored matrix to improve palatability. The composition may be consumed before, during, and/or after a meal for attenuation of post-prandial rise in plasma glucose, triglyceride levels, and cholesterol levels and reduction of risk of chronic metabolic diseases.

Abstract: Compounds are of the structure of Formula (II) wherein: each X is —C(?O)—; R1 is a C1-C18 alkyl polyol; R2 is a saccharide group of formula (G)p; G is a monosaccharide residue, where (i) at least one of the —OH groups in (G)p is substituted by a halogen atom, and (ii) the saccharide group of formula (G)p is linked to —O— through a —CH2 group; p is 1 or 2; and m is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10. The compounds are effective in treating hepatotoxicity and fatty liver diseases.

Abstract: The present invention relates to methods of treating or ameliorating a neurodegenerative disease, such as Parkinson's disease or multiple sclerosis, with a compound according to Formula (I) to (V), or with a compound according to Formula (VI), or a pharmaceutically acceptable salt or solvate thereof, for example, vidofludimus, which acts as a Nurr1 agonist.

Abstract: A method of compounding a topical cream includes combining ingredients including lidocaine hydrochloride, 4%, topical solution, diclofenac sodium, 1.5%, topical solution, lidocaine hydrochloride USP powder, and diclofenac sodium powder.

Abstract: The present invention relates to a composition of (S)-3-aminomethyl-5-methylhexanoic acid or a pharmaceutically acceptable salt thereof, and riluzole. The composition has broad application prospects in the manufacture of a medicament for treating neuropathic pain.

Abstract: Provided herein are methods of treating cancer and fibrosis in a patient. The cancer may be prostate cancer. The fibrosis may be cystitis arising from a cancer therapy, such as from treatment of prostate cancer. The methods involve activation of senescent cells, such as senescent cancer cells with a soluble guanylate cyclase activator. The treatment with the soluble guanylate cyclase activator may be a primary therapy or an adjuvant therapy to a primary cancer therapy such as a chemotherapy or radiation therapy. The treatment may be administered after completion of a primary cancer therapy.

Abstract: The present disclosure generally relates to systems and methods for delivering lactate and phenylalanine, and/or N-lactoyl-phenylalanine and/or other N-lactoyl amino acids to a subject. In some cases, these may be used for appetite control, weight loss, treating or preventing obesity, or for other metabolic-related diseases. In addition, certain embodiments are generally directed to treatments that can be delivered using topical compositions applied to the skin. For example, in some cases, the composition includes lecithin and/or other components that may facilitate delivery through the skin. Further, certain embodiments may include active ingredients such as tributyrin or 2,6-dimethyl-L-tyrosine, which may interact with lactate and phenylalanine, and/or N-lactoyl-phenylalanine and/or other N-lactoyl amino acids. Compositions such as these may be used in certain embodiments, for example, to suppress a subject's appetite, etc.

Abstract: A method of stimulating ventilatory and/or respiratory drive in a subject in need thereof includes administering to the subject a therapeutically effective amount of a composition comprising an glutathione alkyl ester, adduct thereof, or pharmaceutically acceptable salt, tautomer, or solvate thereof.